Merck Ties Up With Zhifei To Distribute Gardasil In China, But What Happened To Sinopharm?
This article was originally published in PharmAsia News
Merck has expanded its collaboration with Zhifei, its vaccine partner in China, by signing a three-year RMB 4.5 billion distribution deal for HPV vaccine Gardasil. But left unanswered is whether Merck will walk away from an intended partnership with Sinopharm it had previously emphasized.
You may also be interested in...
Vaccines Shakeup Continues In China: NT Pharma Backs Away From GSK
SHANGHAI - China's largest vaccine distributor China NT Pharma Group announced Aug. 17 it will not renew its master distribution contract with its largest customer GlaxoSmithKline PLC, in part, it appears, due to burdens created by the new China Pharmacopeia that was issued at the end of 2010
Merck Emerging Markets President Kevin Ali On The Branded Generics Business: An Interview With PharmAsia News (Part 2 of 2)
When Merck & Co. Inc. Emerging Markets President Kevin Ali speaks of innovation, it is emblematic of Merck's deep-rooted focus on new drug discovery, but the veteran executive now sees opportunities in the differentiated, branded generics segment. On a recent visit to India, Ali spoke to PharmAsia News' India Bureau about incrementally innovative drugs, access to affordable medicines and also Merck's plans in the BRIC-MT nations.
Merck Teams Up With Sinopharm On Vaccines As It Gears Up For Gardasil Approval In China
HONG KONG - U.S.-based Merck and China's Sinopharm plan to work together to develop vaccines in China under a preliminary deal that could ultimately see Sinopharm marketing more of the pharmaceutical giant's products in Asia's most populous nation